Cargando…

FAM225B Is a Prognostic lncRNA for Patients with Recurrent Glioblastoma

OBJECTIVE: The overall survival of patients with recurrent glioblastoma (rGBM) is quite different, so clinical outcome prediction is necessary to guide personalized clinical treatment for patients with rGBM. The expression level of lncRNA FAM225B was analyzed to determine its prognostic value in rGB...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Junsheng, Zhang, Qian, Ge, Peicong, Zeng, Chaofan, Lin, Fa, Wang, Wen, Zhao, Jizong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7704151/
https://www.ncbi.nlm.nih.gov/pubmed/33299501
http://dx.doi.org/10.1155/2020/8888085
_version_ 1783616761918128128
author Li, Junsheng
Zhang, Qian
Ge, Peicong
Zeng, Chaofan
Lin, Fa
Wang, Wen
Zhao, Jizong
author_facet Li, Junsheng
Zhang, Qian
Ge, Peicong
Zeng, Chaofan
Lin, Fa
Wang, Wen
Zhao, Jizong
author_sort Li, Junsheng
collection PubMed
description OBJECTIVE: The overall survival of patients with recurrent glioblastoma (rGBM) is quite different, so clinical outcome prediction is necessary to guide personalized clinical treatment for patients with rGBM. The expression level of lncRNA FAM225B was analyzed to determine its prognostic value in rGBMs. METHODS: We collected 109 samples of Chinese Glioma Genome Atlas (CGGA) RNA sequencing dataset and divided into training set and validation set. Then, we analyzed the expression of FAM225B, clinical characteristics, and overall survival (OS) information. Kaplan-Meier survival analysis was used to estimate the OS distributions. The prognostic value of FAM225B in rGBMs was tested by univariate and multivariate Cox regression analyses. Moreover, we analyzed the biological processes and signaling pathways of FAM225B. RESULTS: We found that FAM225B was upregulated in rGBMs (P = 0.0009). The expression of FAM225B increased with the grades of gliomas (P < 0.0001). The OS of rGBMs in the low-expression group was significantly longer than that in the high-expression group (P = 0.0041). Similar result was found in the training set (P = 0.0340) and verified in the validation set (P = 0.0292). In multivariate Cox regression analysis, FAM225B was identified to be an independent prognostic factor for rGBMs (P = 0.003). Biological process and KEGG pathway analyses implied FAM225B mainly played a functional role on transcription, regulation of transcription, cell migration, focal adhesion, etc. CONCLUSIONS: FAM225B is expected to be as a new prognostic biomarker for the identification of rGBM patients with poor outcome. And our study provided a potential therapeutic target for rGBMs.
format Online
Article
Text
id pubmed-7704151
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-77041512020-12-08 FAM225B Is a Prognostic lncRNA for Patients with Recurrent Glioblastoma Li, Junsheng Zhang, Qian Ge, Peicong Zeng, Chaofan Lin, Fa Wang, Wen Zhao, Jizong Dis Markers Research Article OBJECTIVE: The overall survival of patients with recurrent glioblastoma (rGBM) is quite different, so clinical outcome prediction is necessary to guide personalized clinical treatment for patients with rGBM. The expression level of lncRNA FAM225B was analyzed to determine its prognostic value in rGBMs. METHODS: We collected 109 samples of Chinese Glioma Genome Atlas (CGGA) RNA sequencing dataset and divided into training set and validation set. Then, we analyzed the expression of FAM225B, clinical characteristics, and overall survival (OS) information. Kaplan-Meier survival analysis was used to estimate the OS distributions. The prognostic value of FAM225B in rGBMs was tested by univariate and multivariate Cox regression analyses. Moreover, we analyzed the biological processes and signaling pathways of FAM225B. RESULTS: We found that FAM225B was upregulated in rGBMs (P = 0.0009). The expression of FAM225B increased with the grades of gliomas (P < 0.0001). The OS of rGBMs in the low-expression group was significantly longer than that in the high-expression group (P = 0.0041). Similar result was found in the training set (P = 0.0340) and verified in the validation set (P = 0.0292). In multivariate Cox regression analysis, FAM225B was identified to be an independent prognostic factor for rGBMs (P = 0.003). Biological process and KEGG pathway analyses implied FAM225B mainly played a functional role on transcription, regulation of transcription, cell migration, focal adhesion, etc. CONCLUSIONS: FAM225B is expected to be as a new prognostic biomarker for the identification of rGBM patients with poor outcome. And our study provided a potential therapeutic target for rGBMs. Hindawi 2020-11-22 /pmc/articles/PMC7704151/ /pubmed/33299501 http://dx.doi.org/10.1155/2020/8888085 Text en Copyright © 2020 Junsheng Li et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Li, Junsheng
Zhang, Qian
Ge, Peicong
Zeng, Chaofan
Lin, Fa
Wang, Wen
Zhao, Jizong
FAM225B Is a Prognostic lncRNA for Patients with Recurrent Glioblastoma
title FAM225B Is a Prognostic lncRNA for Patients with Recurrent Glioblastoma
title_full FAM225B Is a Prognostic lncRNA for Patients with Recurrent Glioblastoma
title_fullStr FAM225B Is a Prognostic lncRNA for Patients with Recurrent Glioblastoma
title_full_unstemmed FAM225B Is a Prognostic lncRNA for Patients with Recurrent Glioblastoma
title_short FAM225B Is a Prognostic lncRNA for Patients with Recurrent Glioblastoma
title_sort fam225b is a prognostic lncrna for patients with recurrent glioblastoma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7704151/
https://www.ncbi.nlm.nih.gov/pubmed/33299501
http://dx.doi.org/10.1155/2020/8888085
work_keys_str_mv AT lijunsheng fam225bisaprognosticlncrnaforpatientswithrecurrentglioblastoma
AT zhangqian fam225bisaprognosticlncrnaforpatientswithrecurrentglioblastoma
AT gepeicong fam225bisaprognosticlncrnaforpatientswithrecurrentglioblastoma
AT zengchaofan fam225bisaprognosticlncrnaforpatientswithrecurrentglioblastoma
AT linfa fam225bisaprognosticlncrnaforpatientswithrecurrentglioblastoma
AT wangwen fam225bisaprognosticlncrnaforpatientswithrecurrentglioblastoma
AT zhaojizong fam225bisaprognosticlncrnaforpatientswithrecurrentglioblastoma